Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Biochemical Pharmacology|July 22, 2008
Bcl-2 family members as molecular targets in cancer therapyIsabel Marzo, Javier Naval
Biochemical Pharmacology|July 27, 2013
Antimitotic drugs in cancer chemotherapy: promises and pitfallsIsabel Marzo, Javier Naval
The Journal of Biological Chemistry|January 4, 2013
Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementationLaura Vela, Oscar Gonzalo, Javier Naval, et al.
Molecular Immunology|June 30, 2006
Apoptosis by IL-2 deprivation in human CD8+ T cell blasts predominates over death receptor ligation, requires Bim expression and is associated with Mcl-1 lossAlberto Bosque, Isabel Marzo, Javier Naval, et al.
Leukemia Research|October 8, 2011
Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidyPatricia Balsas, Patricia Galán-Malo, Isabel Marzo, et al.
Biochemical Pharmacology|January 11, 2012
Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancerLuis Martinez-Lostao, Isabel Marzo, Alberto Anel, et al.
Molecular Pharmacology|March 2, 2005
Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 eliminationMaría Gómez-Benito, Isabel Marzo, Alberto Anel, et al.
Trends in Cancer|May 28, 2020
Novel Forms of Immunomodulation for Cancer TherapyAlfonso Serrano-Del Valle, Javier Naval, Alberto Anel, et al.
Frontiers in Cell and Developmental Biology|May 2, 2019
Immunogenic Cell Death and Immunotherapy of Multiple MyelomaAlfonso Serrano-Del Valle, Alberto Anel, Javier Naval, et al.
Cells|March 11, 2023
Study of the Bcl-2 Interactome by BiFC Reveals Differences in the Activation Mechanism of Bax and BakÓscar Gonzalo, Andrea Benedi, Laura Vela, et al.
Pageof 5